The modern approach for treating melanocortin obesity is designing MC4R agonists [34]; however, MC4R agonists are only effective when upstream, but not downstream, MC4R signaling is impaired, and, in addition, they can cause side effects [34]. This evidence concerns the gene MC4R and obesity disorder.